Serum immunoglobulins in chronic lymphocytic leukemia

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by the accumulation of mature lymphocytes.
• Immunoglobulin levels are crucial in assessing B-cell function and immune status.
• Understanding immunoglobulin dynamics in CLL is important for disease management.

Purpose of the Study:

• To investigate changes in serum immunoglobulin (IgG, IgA, IgM) levels during the course of CLL.
• To correlate these immunoglobulin changes with clinical and laboratory parameters.
• To assess the prognostic value of immunoglobulin levels and their fluctuations in CLL patients.

Main Methods:

• Periodic determination of serum immunoglobulin levels (IgG, IgA, IgM) in 70 CLL patients.
• Correlation analysis with clinical data (disease stage, treatment) and laboratory parameters (age, sex, leukocyte count).

Main Results:

• Significant decrease in IgG and IgA levels as CLL disease progressed.
• Low IgG at diagnosis (18.7%) increased to ~50% by six years.
• IgM levels increased in 43% of patients; four developed monoclonal fractions.
• Immunoglobulin changes did not correlate with age, sex, or initial leukocyte count.
• Disease stage and chemotherapy augmented the drop in immunoglobulin levels.
• Neither initial nor subsequent immunoglobulin levels showed significant prognostic value.

Conclusions:

• Serum IgG and IgA levels decline with CLL progression.
• IgM may increase, sometimes with monoclonal fraction appearance.
• Chemotherapy and advanced disease exacerbate immunoglobulin reduction.
• Immunoglobulin levels and changes lack significant prognostic value in CLL.